Serine
Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
pipeline Target constitutes close to 6 molecules. Out of which approximately 5
molecules are developed by companies and remaining by the
universities/institutes.
The
latest report Serine Protein Kinase ATM - Pipeline Review, H1 2018, outlays
comprehensive information on the Serine Protein Kinase ATM (Ataxia
Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete
with analysis by indications, stage of development, mechanism of action (MoA),
route of administration (RoA) and molecule type.
Serine
Protein Kinase ATM (Ataxia
Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase ATM is a
serine/threonine protein kinase. It activates checkpoint signaling upon double
strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing
ultraviolet a light (UVA), thereby acting as a DNA damage sensor. It plays a
role in replication-dependent histone mRNA degradation. It binds DNA ends.
The
molecules developed by companies in Phase I, Preclinical and Discovery stages
are 3, 1 and 1 respectively. Similarly, the universities portfolio in
Preclinical stages comprises 1 molecules, respectively. Report covers products
from therapy areas Oncology and Ophthalmology which include indications Head
And Neck Cancer, Adenocarcinoma, Colorectal Cancer, Gastric Cancer,
Glioblastoma Multiforme (GBM), Herpetic Keratitis, Human Papillomavirus (HPV)
Associated Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Solid Tumor and
Squamous Cell Carcinoma.
Furthermore,
this report also reviews key players involved in Serine Protein Kinase ATM
(Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics
development with respective active and dormant or discontinued projects. Driven
by data and information sourced from proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources.
The
report provides a snapshot of the global therapeutic landscape for Serine
Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)
The
report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM
or EC 2.7.11.1) targeted therapeutics under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in Serine Protein Kinase ATM (Ataxia
Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists
all their major and minor projects
The
report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM
or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route
of administration (RoA) and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to Serine Protein Kinase ATM
(Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204
No comments:
Post a Comment